Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
复制标题
瑞波西汀与氟西汀：疗效和耐受性概述。
DOI：
--
复制
发表时间：
1998
影响因子：
5.3
通讯作者：
J. Massana
中科院分区：
文献类型：
--
作者：
J. Massana
5-羟色胺选择性再摄取抑制剂(SSRIs)被广泛用于治疗抑郁症，与抑制5-羟色胺和去甲肾上腺素再摄取的三环抗抑郁药相比，SSRIs具有耐受性更好的优点。在此背景下，进行了2项临床研究，比较了瑞波西汀和氟西汀的疗效和耐受性。瑞波西汀是一种选择性去甲肾上腺素再摄取抑制剂，氟西汀是一种SSRI。两项研究均为双盲、随机、平行分组、多中心设计。其中一组包括安慰剂对照组。549例住院或门诊或日间医院就诊的重度抑郁症患者接受瑞波西汀(8~10 mg/d)或氟西汀(20~40 mg/d)治疗8周。瑞波西汀和氟西汀的总体疗效相似，但优于安慰剂，这是通过汉密尔顿抑郁总分评定量表的平均降幅来评估的。与氟西汀相比，瑞波西汀在重症患者中显示出更好的疗效，并与社会功能的更大改善有关，特别是在行动动机和负面自我认知方面。两种疗法的耐受性都很好。总而言之，瑞波西汀是一种有效且耐受性良好的抗抑郁药，在治疗重症患者和改善社会功能方面优于氟西汀。
Serotonin selective reuptake inhibitors (SSRIs) are widely used to treat depression and offer the advantage of being better tolerated compared with tricyclic antidepressants, which inhibit both serotonin and norepinephrine reuptake. Against this background, 2 clinical studies were conducted comparing the efficacy and tolerability of reboxetine, a selective norepinephrine reuptake inhibitor, with fluoxetine, an SSRI. Both studies were of double-blind, randomized, parallel-group, multicenter design. One included a placebo control group. Five hundred forty-nine patients with major depression, under inpatient care or attending outpatient or day hospital clinics, received reboxetine (8-10 mg/day) or fluoxetine (20-40 mg/day) over 8 weeks. The overall efficacy of reboxetine and fluoxetine was similar, and superior to placebo, as assessed by the mean reduction in Hamilton Rating Scale for Depression total score. Reboxetine demonstrated superior efficacy compared with fluoxetine in severely ill patients and was associated with greater improvement in social functioning, especially in terms of motivation toward action and negative self-perception. Both treatments were well tolerated. In summary, reboxetine is an effective and well-tolerated antidepressant and is superior to fluoxetine in the treatment of severely ill patients and in terms of improving social functioning.